Holy Stone Healthcare participates in the Chicago 2018 AACR Annual Meeting (2018/4/14-4/18) poster presentation. Dr. Eskouhie Tchaparian will promote the company’s new drug, CA102N, targeting colorectal cancer.
Poster Abstract Number: #7883
Subject: Evaluation of antitumor efficacy of CA102N, H-Nim and hyaluronic acid (HA) conjugate, alone or in combination with 5-fluorouracil (5-FU) in in vivo human colorectal cancer models
The American Association for Cancer Research (AACR) was founded in 1907 "to further the investigation and spread the knowledge of cancer." Today, the AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and collaboration.
For more information about the AACR Annual Meeting 2018, please visit: